Skip to main content
Erschienen in: Abdominal Radiology 1/2017

23.08.2016

Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn’s disease in patients treated with anti-TNF treatment

verfasst von: Makoto Naganuma, Shigeo Okuda, Tadakazu Hisamatsu, Katsuyoshi Matsuoka, Kiyoto Mori, Naoki Hosoe, Yoshihiro Nakazato, Haruhiko Ogata, Takanori Kanai

Erschienen in: Abdominal Radiology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

MR enterography (MRE) is useful for evaluating transmural lesions and extra-intestinal complications of Crohn’s disease (CD). The aim of this study was to prospectively evaluate whether MRE could detect severe strictures and inflammatory lesions in patients who lost the responsiveness to anti-TNF treatment and whether MRE could predict prognosis of CD patients with clinical remission.

Patients and methods

MRE were conducted in 50 patients who were treated with infliximab or adalimumab. The main aims of this study were as follows; (1) to compare the rates of CD lesions of the patients with clinical remission and active disease at the baseline and (2) to assess the MRE findings that were predictors of clinical recurrence among patients with clinical remission at the baseline.

Results

The MRE detection rates of markedly increased contrast uptake, severe strictures, and the presence of ulcers were significantly higher in patients with Crohn Disease Activity Index ≥150 than in patients with clinical remission. Over a mean follow-up of 18.2 months, the absence of ulceration (p = 0.001) or severe stricture (p = 0.01) prolonged clinical recurrence among patients with clinical remission at baseline. Expected duration of recurrence significantly prolonged in patients with total magnetic resonance index of activity (MaRIA) <36.3 [29.8 months (95% CI 23.7–35.9)] than in patients with total MaRIA ≥36.3 (13.9 months (95% CI 7.7–20.1). A cut-off value of total MaRIA score of 36.3 had a sensitivity of 75% and specificity of 70% for predicting recurrence.

Conclusion

Findings of ulceration and severe stricture on MRE predict prognosis of CD patients who were treated with anti-TNF treatment. MRE might be useful for making treatment decisions in patients who lost the effectiveness of medical treatments.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Targan SR, Hanauer SB, van Deventer SJ, et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 337:1029–1035CrossRefPubMed Targan SR, Hanauer SB, van Deventer SJ, et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 337:1029–1035CrossRefPubMed
2.
Zurück zum Zitat Hanauer SB, Feagan BG, Lichtenstein GR, et al. (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549CrossRefPubMed Hanauer SB, Feagan BG, Lichtenstein GR, et al. (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549CrossRefPubMed
3.
Zurück zum Zitat Gisbert JP, Panés J (2009) Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 104:760–767CrossRefPubMed Gisbert JP, Panés J (2009) Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 104:760–767CrossRefPubMed
4.
Zurück zum Zitat Fidder H, Schnitzler F, Ferrante M, et al. (2009) Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58:501–508CrossRefPubMed Fidder H, Schnitzler F, Ferrante M, et al. (2009) Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58:501–508CrossRefPubMed
5.
Zurück zum Zitat Allez M, Karmiris K, Louis E, et al. (2010) Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 4:355–366CrossRefPubMed Allez M, Karmiris K, Louis E, et al. (2010) Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 4:355–366CrossRefPubMed
6.
Zurück zum Zitat Naganuma M, Hosoe N, Ogata H (2014) Inflammatory bowel disease and novel endoscopic technologies. Dig Endosc 26(Suppl 1):20–28CrossRefPubMed Naganuma M, Hosoe N, Ogata H (2014) Inflammatory bowel disease and novel endoscopic technologies. Dig Endosc 26(Suppl 1):20–28CrossRefPubMed
7.
Zurück zum Zitat Rimola J, Rodriguez S, Garcia-Bosch O, et al. (2009) Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut 58:1113–1120CrossRefPubMed Rimola J, Rodriguez S, Garcia-Bosch O, et al. (2009) Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut 58:1113–1120CrossRefPubMed
8.
Zurück zum Zitat Lee SS, Kim AY, Yang SK, et al. (2009) Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 251:751–761CrossRefPubMed Lee SS, Kim AY, Yang SK, et al. (2009) Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 251:751–761CrossRefPubMed
9.
Zurück zum Zitat Siddiki HA, Fidler JL, Fletcher JG, et al. (2009) Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn’s disease. AJR Am J Roentgenol 193:113–121CrossRefPubMed Siddiki HA, Fidler JL, Fletcher JG, et al. (2009) Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn’s disease. AJR Am J Roentgenol 193:113–121CrossRefPubMed
10.
Zurück zum Zitat Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. (2011) Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis 17:1073–1080CrossRefPubMed Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. (2011) Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis 17:1073–1080CrossRefPubMed
11.
Zurück zum Zitat Jensen MD, Kjeldsen J, Rafaelsen SR, Nathan T (2011) Diagnostic accuracies of MR enterography and CT enterography in symptomatic Crohn’s disease. Scand J Gastroenterol 46:1449–1457CrossRefPubMed Jensen MD, Kjeldsen J, Rafaelsen SR, Nathan T (2011) Diagnostic accuracies of MR enterography and CT enterography in symptomatic Crohn’s disease. Scand J Gastroenterol 46:1449–1457CrossRefPubMed
12.
Zurück zum Zitat Hyun SB, Kitazume Y, Nagahori M, et al. (2011) MR enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn’s disease. Inflam Bowel Dis 17:1063–1072CrossRef Hyun SB, Kitazume Y, Nagahori M, et al. (2011) MR enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn’s disease. Inflam Bowel Dis 17:1063–1072CrossRef
13.
Zurück zum Zitat Castiglione F, Mainenti PP, De Palma GD, et al. (2013) Noninvasive diagnosis of small bowel Crohn’s disease: direct comparison of bowel sonography and magnetic resonance enterography. Inflamm Bowel Dis 19:991–998CrossRefPubMed Castiglione F, Mainenti PP, De Palma GD, et al. (2013) Noninvasive diagnosis of small bowel Crohn’s disease: direct comparison of bowel sonography and magnetic resonance enterography. Inflamm Bowel Dis 19:991–998CrossRefPubMed
14.
Zurück zum Zitat Naganuma M, Hisamatsu T, Kanai T, Ogata H (2015) Magnetic resource enterography in patients with Crohn’s disease. Expert Rev Gastroenterol Hepatol 9:37–45CrossRefPubMed Naganuma M, Hisamatsu T, Kanai T, Ogata H (2015) Magnetic resource enterography in patients with Crohn’s disease. Expert Rev Gastroenterol Hepatol 9:37–45CrossRefPubMed
15.
Zurück zum Zitat Panes J, Bouhnik Y, Reinisch W, et al. (2013) Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 7:556–585CrossRefPubMed Panes J, Bouhnik Y, Reinisch W, et al. (2013) Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 7:556–585CrossRefPubMed
16.
Zurück zum Zitat Van Assche G, Herrmann KA, Louis E, et al. (2013) Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn’s disease. J Crohns Colitis 7:950–957CrossRefPubMed Van Assche G, Herrmann KA, Louis E, et al. (2013) Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn’s disease. J Crohns Colitis 7:950–957CrossRefPubMed
17.
Zurück zum Zitat Ordás I, Rimola J, Rodríguez S, et al. (2014) Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology 146:374–382CrossRefPubMed Ordás I, Rimola J, Rodríguez S, et al. (2014) Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology 146:374–382CrossRefPubMed
18.
Zurück zum Zitat Takenaka K, Ohtsuka K, Kitazume Y, et al. (2014) Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn’s disease. Gastroenterology 147:334–342CrossRefPubMed Takenaka K, Ohtsuka K, Kitazume Y, et al. (2014) Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn’s disease. Gastroenterology 147:334–342CrossRefPubMed
19.
Zurück zum Zitat Hibi T, Sakuraba A, Watanabe M, et al. (2014) C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol 49:254–262CrossRefPubMed Hibi T, Sakuraba A, Watanabe M, et al. (2014) C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol 49:254–262CrossRefPubMed
20.
Zurück zum Zitat Hibi T, Sakuraba A, Watanabe M, et al. (2012) Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn’s disease. Inflamm Bowel Dis 18:1480–1487CrossRefPubMed Hibi T, Sakuraba A, Watanabe M, et al. (2012) Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn’s disease. Inflamm Bowel Dis 18:1480–1487CrossRefPubMed
21.
Zurück zum Zitat Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 4:1248–1254CrossRefPubMed Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 4:1248–1254CrossRefPubMed
22.
Zurück zum Zitat Afif W, Loftus EV Jr, Faubion WA, et al. (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105:1133–1139CrossRefPubMed Afif W, Loftus EV Jr, Faubion WA, et al. (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105:1133–1139CrossRefPubMed
23.
Zurück zum Zitat Roblin X, Marotte H, Rinaudo M, et al. (2014) Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12:80–84CrossRefPubMed Roblin X, Marotte H, Rinaudo M, et al. (2014) Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12:80–84CrossRefPubMed
24.
Zurück zum Zitat Frøslie KF, Jahnsen J, Moum BA, Vatn MH (2007) IBSEN group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133:412–422CrossRefPubMed Frøslie KF, Jahnsen J, Moum BA, Vatn MH (2007) IBSEN group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133:412–422CrossRefPubMed
25.
Zurück zum Zitat Rutgeerts P, Diamond RH, Bala M, et al. (2006) Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 63:433–442CrossRefPubMed Rutgeerts P, Diamond RH, Bala M, et al. (2006) Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 63:433–442CrossRefPubMed
26.
Zurück zum Zitat Schnitzler F, Fidder H, Ferrante M, et al. (2009) Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 15:1295–1301CrossRefPubMed Schnitzler F, Fidder H, Ferrante M, et al. (2009) Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 15:1295–1301CrossRefPubMed
27.
Zurück zum Zitat Eder P, Michalak M, Katulska K, et al. (2015) Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn’s disease treated with anti-tumor necrosis factor antibodies. Sci Rep 20(5):10223CrossRef Eder P, Michalak M, Katulska K, et al. (2015) Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn’s disease treated with anti-tumor necrosis factor antibodies. Sci Rep 20(5):10223CrossRef
Metadaten
Titel
Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn’s disease in patients treated with anti-TNF treatment
verfasst von
Makoto Naganuma
Shigeo Okuda
Tadakazu Hisamatsu
Katsuyoshi Matsuoka
Kiyoto Mori
Naoki Hosoe
Yoshihiro Nakazato
Haruhiko Ogata
Takanori Kanai
Publikationsdatum
23.08.2016
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 1/2017
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-0878-5

Weitere Artikel der Ausgabe 1/2017

Abdominal Radiology 1/2017 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.